China News Service, Beijing, September 28 (Reporter Li Yanan) "With the improvement of people's health awareness and the advancement of diagnosis and treatment technology, the rate of consultation of patients with rheumatism has increased in recent years. Although the situation of'less drugs' has improved, However, the problem of'lack of medical care' is still the biggest dilemma facing the rheumatism community." Professor Zeng Xiaofeng, director of the National Clinical Research Center for Skin and Immune Diseases and director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, recently presented at the 10th CSTAR/CRDC Forum and China It was pointed out at the CRCA annual meeting of the Alliance of Rheumatology and Immunology.
According to reports, as a serious chronic disease, rheumatism and immunological diseases have an increasing demand for diagnosis and treatment of patients. For this reason, the National Health Commission has issued the "Guidelines for the Construction and Management of Rheumatology and Immunology Departments in General Hospitals", suggesting that qualified general hospitals should follow the requirements , Strengthen the construction and management of rheumatism and immunology, and continuously improve the diagnosis and treatment of rheumatism and immunity.
Zeng Xiaofeng said that in recent years, the rate of consultation of patients with rheumatism has become higher and higher, and the situation of fewer drugs has improved, but the problem of lack of medicine is still the biggest dilemma facing the rheumatism community.
With the promulgation of relevant documents of the National Health Commission, the discipline of rheumatism and immunological diseases in China has developed rapidly in recent years, but there is still a large gap. In the future, it will be clinically oriented and based on the establishment of databases to provide more information for national policies. Much support.
In July 2020, China’s first "Rheumatoid Arthritis Development Report" initiated and compiled by the National Clinical Research Center for Skin and Immune Diseases and the National Rheumatism Data Center was officially released, fully displaying the latest rheumatoid arthritis (RA) Epidemiological data, clinical characteristics, current status of diagnosis and treatment, subject resources and development status provide the basis for the formulation of health policies and resource allocation of national health management departments.
As one of the authors of the report, Professor Tian Xinping from the Department of Rheumatology and Immunology, Peking Union Medical College Hospital, said, “For a long time, the lack of sufficient RA pharmacoeconomic research support and the lack of evidence-based medical evidence diagnosis and treatment guidelines have caused serious treatment. Delays, coupled with the characteristics of RA with many diseases, long duration, many moderate to severe patients, and many concurrent diseases, have brought great challenges to the prevention and treatment of RA and the improvement of long-term prognosis. At the same time, the disease awareness is low. Problems such as non-standardized diagnosis and treatment, and large gaps in professional practitioners also need to be solved urgently. Therefore, it is imperative to establish a standardized rheumatic immune disease diagnosis and treatment service system and improve the popular science education of RA patients."
In this event, the National Clinical Research Center for Skin and Immunological Diseases, the Chinese Association of Rheumatology and Immunology Physicians Branch, and the Chinese Rheumatology and Immunology Medical Consortium Alliance signed a strategic cooperation project with Pfizer for the development and promotion of the China Rheumatism and Immunology Diagnosis and Treatment Service System Letter of Intent (C-RISE) to promote the accelerated development and construction of rheumatism and immunology.
According to Zeng Xiaofeng, the C-RISE project will be implemented in phases, planned and step-by-step in a three-year cycle, focusing on three directions: personnel training and department construction, clinical diagnosis and treatment standards, and real-world research, and building classification Diagnosis and treatment system and medical quality control system.
The project is expected to support about 400 tertiary hospitals without rheumatology and immunology departments in the establishment and construction of new rheumatology and immunology departments. In the form of advanced training classes for academic leaders, more than 200 backbone talents in the core area will be trained to support talent reserves and Construction of a new department of the hospital's rheumatism and immunology department.
Actively carry out academic exchanges related to rheumatism and immune diseases through academic platforms, and conduct basic training on guidelines for diagnosis and treatment of frequently-occurring common diseases.
In addition, it will cooperate with the China Rheumatoid Arthritis Direct Reporting (CREDIT) platform to provide technical support and continuing medical education (CME) training, develop standardized diagnosis and treatment centers and demonstration centers, and conduct annual standardized treatment level and quality assessments to This forms the annual "diagnosis and treatment status development report" of the disease, and finally serves as the basis for the compilation of the national annual development report of frequently-occurring diseases of rheumatism and immunity.
At the beginning of the project, a research platform for a hierarchical diagnosis and treatment system and a medical quality control system will be built to support patients’ chronic disease management practices, gradually build a chronic disease management model, and promote the rise of RA as a national chronic disease management policy, and finally establish and develop a hierarchical diagnosis and treatment system and medical quality Control system.
"Through the implementation of this project, we can not only solve the problem of lack of medical care, but also have a more comprehensive and clear understanding of the prevalence of rheumatism in China, and form a guideline or expert consensus on the diagnosis and treatment of rheumatism in China. The formulation of diagnosis and treatment guidelines, new drug research and development, medical reform policies, etc. provide important big data service support, and finally form a rheumatism development path with Chinese characteristics, and help rheumatoid immune disease management and prevention and control to'all-round' improvement." Zeng Xiaofeng said.
(Finish)